Dissertations / Theses on the topic 'Digoxin'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 dissertations / theses for your research on the topic 'Digoxin.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.
Alexandrovich, Susan K. "Characterization of monoclonal antibodies against digoxin /." Online version of thesis, 1987. http://hdl.handle.net/1850/10681.
Full textMatthewson, Beryl Ellen. "Digoxin-like immunoreactive substances in the neonate." Thesis, University of British Columbia, 1988. http://hdl.handle.net/2429/28022.
Full textMedicine, Faculty of
Pathology and Laboratory Medicine, Department of
Graduate
Hui, James. "Analysis for digoxin and metabolites in serum and digoxin disposition in the elderly with gastrointestinal disease after two oral dosage forms /." The Ohio State University, 1988. http://rave.ohiolink.edu/etdc/view?acc_num=osu1487587604130428.
Full textHallberg, Pär. "Pharmacogenomics of antihypertensive treatment & clinical pharmacological studies of digoxin treatment /." Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5782.
Full textCavet, Megan Elizabeth. "Intestinal secretion of organic solutes." Thesis, University of Newcastle Upon Tyne, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.318538.
Full textSvensson, Åsa. "Applications of a new logic to old drugs: angiogenesis inhibition in neuroblastoma /." Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2003. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3458.
Full textBARROS, Isabel Cristina Medeiros. "Monitoração terapêutica das concentrações plásmaticas da digoxina em pacientes com insuficiência cardíaca." Universidade Federal de Goiás, 2008. http://repositorio.bc.ufg.br/tede/handle/tde/1703.
Full textIt was investigated the clinical, lab and plasma digoxin concentration profiles in 15 cardiac heart failure (CHF) outpatients of the Cardiac Heart Service of the Goias Federal University Clinical Hospital. It was aimed to know plasma digoxin concentration profile in 15 cardiac heart failure (CHF) outpatients by two analytical methods, taking account clinical, laboratorial, habits, anthropometric data and drug usage. Digoxin dosage was developed by LC/MS/MS and immunoassay methods; questionnaire and consults handbooks were performed. Results and Conclusions: 87% of the patients who over 46 years of age (33% above 61), the masculine majority; the IC of Chagas disease origin presented greater occurrence, followed of the hipertensive and idiopatic (59%); IC functional classroom II (53.33%); hypertension and diabetes had been distinguished as co-morbidities (26.67% and 20%); tobaccoism, overweight and obesity degree I had presented low occurrence. No patients presented relevant clinical data suggestive of digitalis intoxication. No observed changes in biochemical and hematological exams. The ejection fractions were good by means 41.7 ± 9%. Some drugs with interaction potential had been associated to the treatment, apparently without alterations. Statistical significative difference between both methods was observed (P < 0.05, ANOVA, Tukey Test). In the immunoassay method, all the patients were inside of the therapeutical range (0, 5-2, 0 ng/mL), whereas for the LC-MS/MS method, 8 patients they would be in subtherapeutical concentrations. However, no patient presented signals or symptoms of poisoning or inefficacy of the digoxin, demonstrating biological variability. The two methods are useful, since that it has a correlation with the clinical and laboratorial state of the patients.
Investigou-se o perfil clínico, laboratorial e as concentrações de digoxina plasmática em 15 pacientes com insuficiência cardíaca (IC) atendidos no Ambulatório de Insuficiência Cardíaca do HC-UFG. Objetivou-se estudar o perfil de concentrações plasmáticas de digoxina em pacientes com IC, utilizando dois métodos analíticos, e descrever a digoxinemia considerando os dados clínicos, laboratoriais, hábitos, IMC e consumo de medicamentos. A metodologia utilizada consistiu de cromatografia líquida de alta eficiência acoplada a espectrometria de massas (LC/MS/MS) e Imunoensaio, aplicação de questionário e consulta a prontuários. Como resultados, observou-se: 87% dos pacientes maiores que 46 anos de idade (33% acima de 61), a maioria masculina, a IC de origem chagásica apresentou maior ocorrência, seguida da hipertensiva e idiopática (59%); IC classe funcional II (53,33%); hipertensão e diabetes destacaram-se como co-morbidades (26,67% e 20%); tabagismo, sobrepeso e obesidade grau I apresentaram baixa ocorrência. Nenhum dos pacientes apresentou dados clínicos relevantes sugestivos de intoxicação digitálica. Não houve alterações em exames bioquímicos e hematológicos. A fração de ejeção média foi 41,7 ± 9%, portanto nenhum paciente apresentou FE como preditor de mau prognóstico. Vários fármacos com potencial de interação estiveram associados ao tratamento, aparentemente sem alterações. Houve diferença significativa (P < 0,05, ANOVA, Teste de Tukey) entre os métodos analíticos. No método de imunoensaio, todos os pacientes estavam dentro da faixa terapêutica (0,5-2,0 ng/mL), enquanto que pelo método LC-MS/MS, 8 pacientes estariam em sub-dosagens. Entretanto, nenhum paciente apresentou sinais ou sintomas de intoxicação ou de ineficácia da digoxina, demonstrando variabilidade biológica. Os dois métodos são úteis, desde que haja uma correlação com o estado clínico e laboratorial dos pacientes.
Embree, Leanne. "Development of a sensitive, quantitative high-performance liquid chromatographic assay for the measurement of digoxin in patient groups with high levels of digoxin-like immunoreactive substances." Thesis, University of British Columbia, 1989. http://hdl.handle.net/2429/29093.
Full textPharmaceutical Sciences, Faculty of
Graduate
Hallberg, Pär. "Pharmacogenomics of Antihypertensive Treatment & Clinical Pharmacological Studies of Digoxin Treatment." Doctoral thesis, Uppsala universitet, Institutionen för medicinska vetenskaper, 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5782.
Full textVetticaden, Santosh John. "Evaluation of Analytical, Pharmacokinetic and Pharmacodynamic Methods for the Study of Digoxin." VCU Scholars Compass, 1985. http://scholarscompass.vcu.edu/etd/5103.
Full textMurata, Viviane Midori. "Produção e caracterização da porção Fab do anticorpo anti-digoxina utilizando a tecnologia de phage display." Universidade de São Paulo, 2012. http://www.teses.usp.br/teses/disponiveis/87/87131/tde-11062012-083314/.
Full textDigoxin is a pharmaceutical used in the control of cardiac dysfunction. Its therapeutic window is very narrow. To counteract the toxic effect, polyclonal anti-digoxin Fab fragments are commercially available. Our goal was to obtain variants of monoclonal anti-digoxin Fab fragments by phage display technology, which allows the generation of high affinity and specificity antibody fragments. Anti-digoxin Fab fragments combinatorial library was constructed into pComb3X vector from total RNA of anti-digoxin hybridoma. Six clones were isolated and the heavy chain presented the same sequence. For the light chain, 2 clones were identical, one was a pseudogene and other one presented a distinct amino acid in the CDR2. Four clones presenting variations in the framework 1 were induced to express soluble Fab fragments, all positive for anti-digoxin binding in ELISA assays and Western blotting. The specific binding of the antibody was further confirmed by BIAcore, which allowed ranking of the clones.
Tzou, Meir-Chyun. "Development and validation of a specific high performance liquid chromatographic method for determination of digoxin and metabolites in serum and its applications to digoxin metabolism and therapeutic drug monitoring studies in humans /." The Ohio State University, 1994. http://rave.ohiolink.edu/etdc/view?acc_num=osu1487854314873705.
Full textBaek, Myoungki. "Dynamic system analysis of receptor interaction and effectuation mechanisms of digoxin in the rat heart." [S.l.] : [s.n.], 2005. http://deposit.ddb.de/cgi-bin/dokserv?idn=975656562.
Full textWeitkamp, Christine. "Warum zeigen die Herzglykoside Ouabain und Digoxin unterschiedliche Kreislaufwirkung? Charakterisierung eines mutmasslichen Herzglykosid-Bindungsproteins im Serum und Analyse der Wirkung beider Steroide auf die Endothelin-1- und NO-Freisetzung aus arteriellen Endothelzellen /." Wettenberg : VVB Laufersweiler, 2005. http://deposit.ddb.de/cgi-bin/dokserv?idn=976405792.
Full textGashi, Elida. "Hur påverkar johannesört farmakokinetiken utav warfarin, ciklosporin, digoxin, preventivmedel och teofyllin? Vad har detta för klinisk betydelse?" Thesis, Linnéuniversitetet, Institutionen för naturvetenskap, NV, 2012. http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-18745.
Full textInocencio, André Luís. "Purificação e caracterização do fragmento Fab anti-digoxina obtido pela técnica de phage display." Universidade de São Paulo, 2016. http://www.teses.usp.br/teses/disponiveis/87/87131/tde-25082016-085639/.
Full textDigoxin is a medication indicated for heart failure treatment. Its therapeutic window is narrow, being responsible for intoxication cases. The only antidote available for the detoxification is a polyclonal antibody - DigiFab® in Fab format. Its use is effective, but costly. Bacterial clones producing anti-digoxin monoclonal Fab fragments were previously obtained by our group using phage display technology. In this work the Fab variants of the 4 clones were expressed in E.coli to establish the purification method. The purified fragments were characterized regarding the affinity to the antigen and the specificity through inhibition assays with digoxin, digitoxin, digoxigenin and ouabain. The binding kinetic parameters of Fab fragments of the 4 clones and the commercial product to Dig-BSA conjugate were assessed by SPR. Under the experimental conditions no significant differences were observed among the 4 clones and the commercial product, demonstrating the potential of monoclonal Fab fragments as an antidote to digoxin.
Meseg, Antje [Verfasser]. "Einfluss von Polymorphismen im Multidrug resistance Gen Typ 1 (ABCB1) auf die Single dose Kinetik von Digoxin / Antje Meseg." Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2008. http://d-nb.info/1022941127/34.
Full textHopoate-Sitake, Moana Lee. "A Novel Use of Digoxin Immune Fab Fragment in Identification and Isolation of an Endogenous Digitalis-like Factor Found in Preeclampsia." BYU ScholarsArchive, 2011. https://scholarsarchive.byu.edu/etd/2599.
Full textSvensson, Åsa. "Application of a New Logic to Old Drugs: Angiogenesis Inhibition in Neuroblastoma." Doctoral thesis, Uppsala University, Department of Medical Cell Biology, 2003. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3458.
Full textNeuroblastoma is one of the most common solid cancers of early childhood. In Sweden, approximately 10-15 cases occur annually. The overall five-year neuroblastoma survival in Europe is approximately 45%. Since cancer treatment involves drugs with risks of side effects in the growing child, there is a need for more effective and less toxic drugs. One new approach in cancer treatment is inhibition of tumor angiogenesis, i.e., of new blood vessel growth into the tumor. An angiogenesis inhibitor may be combined with cytostatic drugs to enhance the efficacy. The aim of this study was to investigate how drugs could be used to inhibit angiogenesis and tumor growth in a xenograft model of human neuroblastoma in nude mice.
The tumors express the angiogenesis stimulator vascular endothelial growth factor (VEGF) on both protein and mRNA levels. The angiogenesis inhibitors SU5416 (an inhibitor of VEGF signalling) and TNP-470 (an inhibitor of endothelial cell proliferation) inhibited angiogenesis in our model. TNP-470, however, inhibited angiogenesis without significant reduction of the tumor growth, in contrast to SU5416.
We also discovered that the cytostatic drug CHS 828 could cause regression of neuroblastoma tumors in the model when given orally at a low daily dose, alone or in combination with the angiogenesis inhibitor SU5416 or TNP-470.
Furthermore, a new use of the cardiac glycoside digoxin was found. Digoxin inhibited FGF-2 -stimulated bovine capillary endothelial cell growth in vitro, and inhibited angiogenesis in vivo in the chick chorioallantoic membrane assay (CAM). It also inhibited neuroblastoma growth by approximately 50% in our neuroblastoma model.
In conclusion, CHS 828 and digoxin represent two classes of drugs with potent antitumor effects that may be valuable in treatment of neuroblastoma, either alone or in combination with angiogenesis inhibitors.
Ma, Jie. "Human Endogenous Sodium Pump Inhibitors Measurement, Source, Synthesis and Regulation." BYU ScholarsArchive, 2011. https://scholarsarchive.byu.edu/etd/2953.
Full textNeves, Claodete Hasselstrom. "Efeitos da administração crônica da digoxina e do verapamil sobre o desempenho físico e a estrutura e função cardíaca em ratos submetidos ao treinamento físico intervalado." Universidade Federal de Mato Grosso, 2015. http://ri.ufmt.br/handle/1/682.
Full textApproved for entry into archive by Jordan (jordanbiblio@gmail.com) on 2018-04-27T17:11:37Z (GMT) No. of bitstreams: 1 DISS_2015_Claodete Hasselstrom Neves.pdf: 1544628 bytes, checksum: c8448adc35211604eee744606435547c (MD5)
Made available in DSpace on 2018-04-27T17:11:37Z (GMT). No. of bitstreams: 1 DISS_2015_Claodete Hasselstrom Neves.pdf: 1544628 bytes, checksum: c8448adc35211604eee744606435547c (MD5) Previous issue date: 2015-03-06
O objetivo deste estudo foi investigar os efeitos da administração crônica de digoxina e do verapamil durante treinamento físico intervalado de alta intensidade (TFI) sobre o desempenho físico, capacidade funcional e morfologia cardíaca de ratos. Para tanto, 48 ratos Wistar, com 60 dias de idade, foram aleatoriamente distribuídos em 6 grupos(N=8/grupo): controle, não treinado (C), treinado, sem administração de droga (T), digoxina sem treinamento (DIGO), verapamil sem treinamento (VERA), treinado, com administração de digoxina (TDIGO) e treinado, com administração de verapamil (TVERA). A digoxina e o verapamil foram administrados via gavagem, na dose de 30μg/kg/dia e 5,0 mg/kg/dia respectivamente, durante todo o período experimental. Os grupos T, TDIGO e TVERA foram submetidos a um programa de TFI em esteira rolante durante 60 dias. Foi aplicado o teste de esforço progressivo máximo (TEM) e determinada a concentração sérica de lactato (LAC) sanguíneo. O TFI consistiu de sessões de corrida em esteira rolante 1 h/dia, 5 dias/semana por 60 dias. A intensidade de treino foi 80% da velocidade máxima (Vmáx) atingida no teste de esforço antes do TFI por 8 min e 20% da Vmáx por 2 min. A função cardíaca foi avaliada por ecocardiograma. Foi coletado o músculo esquelético, o músculo cardíaco e a gordura corporal total (GOR) para os dados anatômicos, o ventrículo esquerdo (VE) para análise histológica e o sangue para a análise bioquímica. A comparação entre os grupos foi realizada por meio da análise de variância (ANOVA) e Kruskal Wallis para o esquema de dois fatores independentes, complementada com o teste de Bonferroni, Tukey ou Dunn. O índice de significância considerado foi de 5%. A relação VE/peso corporal final (PCF), o diâmetro diastólico do VE (DDVE) e diâmetro sistólico do VE (DSVE) foram maiores no grupo TDIGO do que o grupo T e DIGO. Os parâmetros do TEM foram maiores e a concentração de LAC foi menor em ratos treinados em relação aos não treinados. A relação GOR/PCF foi menor no TDIGO e TVERA em relação ao DIGO e VERA, respectivamente. A relação VE/PCF foi maior no TVERA em relação ao VERA. O diâmetro interno do VE (DIVE) do grupo T, TDIGO e TVERA foram maiores em relação ao C, o TDIGO teve aumento em relação ao DIGO. O colesterol total e o LDL foram maiores no TDIGO comparado ao DIGO. A área do cardiomiócito foi maior nos grupos VERA e T comparados ao grupo C. Conclusão: O Treinamento intervalado promoveu hipertrofia cardíaca do tipo excêntrica. Entretanto, a administração concomitante de digoxina ou de verapamil não afetaram a morfologia cardíaca, a função cardíaca e o desempenho físico em ratos submetidos ao treinamento.
The aim of this study was to investigate the effects of chronic administration of cardiotonic (digoxin) and the calcium channel blocker (verapamil) during high-intensity interval exercise training (IET) on physical performance, functional capacity and cardiac morphology of rats. For this study, 48 Wistar rats, 60 days old, were randomly distributed into 6 groups (N = 8 / group): control, untrained (C), trained without drug administration (T), digoxin untrained (DIGO), verapamil without training (VERA), trained with digoxin administration (TDIGO) and trained with verapamil administration (TVERA). Digoxin and verapamil were administered by gavage at a dose of 30μg/kg/day and 5.0 mg.kg-1, respectively, throughout the experimental period. The groups T, TDIGO and TVERA underwent a IET program on a treadmill for 60 days. The progressive maximal exercise test was applied (TPM) and determined the serum concentration of lactate (LAC) blood. The IET consisted of sessions running on a treadmill 1 h/day, 5 days/week for 60 days. The training intensity was 80% of the maximum velocity (Vmax) achieved in the stress test before the TAI for 8 min and 20% of Vmax for 2 min. Cardiac function was assessed by echocardiography. Was collected skeletal muscle, cardiac muscle and total body fat (TBF) for anatomical data, the left ventricle (LV) for histological analysis and blood for biochemical analysis. The comparison between groups was performed using analysis of variance (ANOVA) or Kruskal Wallis for the two independent factors, complemented by the Bonferroni test, Tukey or Dunn. The significance level considered was 5%. The ratio VE final body weight (FBW), LV diastolic diameter (LVDD) and LV systolic diameter (LVSD) were higher in TDIGO group than the group T and DIGO. The parameters MET were higher and the concentration of LAC was lower in rats training in relation to the untrained. The relationship GOR/FBW was lower in TDIGO and TVERA compared to DIGO and VERA respectively. The ratio VE/FBW was higher in TVERA compared to VERA. The of the LV inside diameter (LVID) T group, TDIGO and TVERA were higher compared to C, TDIGO had increased compared to DIGO. Total cholesterol and LDL were higher in TDIGO compared to DIGO. The area of cardiomyocytes was higher in VERA and T compared to group C. Conclusion: TAI induced cardiac hypertrophy of the eccentric type. However, concomitant administration of digoxin or verapamil did not affect the cardiac morphology, cardiac function and physical performance in rats submitted to training.
Nguyen, Khoa Thuy Diem. "Energy metabolism in the brain and rapid distribution of glutamate transporter GLAST in astrocytes." Thesis, The University of Sydney, 2008. http://hdl.handle.net/2123/3996.
Full textNguyen, Khoa Thuy Diem. "Energy metabolism in the brain and rapid distribution of glutamate transporter GLAST in astrocytes." University of Sydney, 2008. http://hdl.handle.net/2123/3996.
Full textGlutamate transporters play a role in removing extracellular excitatory neurotransmitter, L-glutamate into the cells. The rate of the uptake depends on the density of the transporters at the membrane. Some studies claimed that glutamate transporters could transit between the cytoplasm and the membrane on a time-scale of minutes. The present study examined the distribution of glutamate transporter GLAST predominantly expressed in rat cortical cultured astrocytes between the membrane and the cytoplasm by using deconvolution microscopy and then analyzing the images. The regulation of the distribution of GLAST was studied in the presence of glutamate transporter substrate (D-aspartate), purinergic receptor activators (α,β-methylene ATP, adenosine), neuroleptic drugs (clozapine, haloperidol), ammonia (hyperammonia) and Na+/K+-ATPase inhibitors (ouabain, digoxin and FCCP). It was demonstrated that the translocation of GLAST towards the plasma membrane was induced by D-aspartate, α,β-methylene ATP, adenosine, clozapine and ammonia (at 100 μM and very high concentrations of 10 mM). However, the inhibition of Na+/K+-ATPase activity had an opposite effect, resulting in redistribution of GLAST away from the membrane. It has previously been claimed that the membrane-cytoplasm trafficking of GLAST was regulated by phosphorylation catalysed by protein kinase C delta (PKC-delta). Involvement of this mechanism has, however, been put to doubt when rottlerin, a PKC-delta inhibitor, used to test the hypothesis showed to inhibit Na+/K+-ATPase-mediated uptake of Rb+, suggesting that rottlerin influenced the activity of Na+/K+-ATPase. As Na+/K+-ATPase converts ATP to energy and pumps Na+, K+ ions, thus helping to maintain normal electrochemical and ionic gradients across the cell membrane. Its inhibition also reduced D-aspartate transport and could impact on the cytoplasm-to-membrane traffic of GLAST molecules. Furthermore, rottlerin decreased the activity of Na+/K+-ATPase by acting as a mitochondrial inhibitor. The present study has focused on the inhibition of Na+/K+-ATPase activity by rottlerin, ouabain and digoxin in homogenates prepared from rat kidney and cultured astrocytes. The activity of Na+/K+-ATPase was measured by the absorption of inorganic phosphate product generated from the hydrolysis of ATP and the fluorescent transition of the dye RH421 induced by the movement of Na+/K+-ATPase. This approach has a potential to test whether the rottlerin effect on Na+/K+-ATPase is a direct inhibition of the enzyme activity. Rottlerin has been found to block the activity of Na+/K+-ATPase in a dose-dependent manner in both rat kidney and astrocyte homogenates. Therefore, rottlerin inhibited the activity of Na+/K+-ATPase directly in a cell-free preparation, thus strongly indicating that the effect was direct on the enzyme. In parallel experiments, ouabain and digoxin produced similar inhibitions of Na+/K+-ATPase activity in rat kidney while digoxin blocked the activity of Na+/K+-ATPase to a greater extent than ouabain in rat cortical cultured astrocytes. In a separate set of experiments, Na+/K+-ATPase in the astrocytic membrane was found to be unsaturated in E1(Na+)3 conformation in the presence of Na+ ions and this could explain the differences between the effects of digoxin and ouabain on the activity of Na+/K+-ATPase in rat astrocytes. In addition, it was found that at low concentrations of rottlerin, the activity of Na+/K+-ATPase was increased rather than inhibited. This effect was further investigated by studying rottlerin interactions with membrane lipids. The activity of Na+/K+-ATPase has been reported to be regulated by membrane lipids. The enzyme activity can be enhanced by increasing fluidity of the lipid membrane. I have, therefore, proposed that rottlerin binds to the membrane lipids and the effects of rottlerin on Na+/K+-ATPase are mediated by changes in the properties (fluidity) of the membrane. The hypothesis was tested by comparing rottlerin and a detergent, DOC (sodium deoxycholate), for their binding to the lipids by using a DMPC (1,2-Dimyristoyl-sn-Glycero-3-Phosphocholine) monolayer technique. DOC has been shown to both increase and inhibit activity of Na+/K+-ATPase in a manner similar to that displayed by rottlerin. The effects of rottlerin and DOC on the DMPC monolayers were studied by measuring the surface pressure of DMPC monolayers and surface area per DMPC molecule. I established that both rottlerin and DOC decreased the surface pressure of DMPC monolayers and increased the surface area per DMPC molecule. This indicates that both rottlerin and DOC penetrated into the DMPC monolayers. If rottlerin can interact with the lipids, changes in fluidity of the lipid membrane cannot be ruled out and should be considered as a possible factor contributing to the effects of rottlerin on the activity of Na+/K+-ATPase. Overall, the study demonstrates that rottlerin is not only a PKC-delta inhibitor but can have additional effects, both on the enzyme activities (Na+/K+-ATPase) and/or on lipid-containing biological structures such as membranes. The findings have implication not only for studies where rottlerin was used as a supposedly specific PKC-delta inhibitor but also for mechanisms of its toxicity.
Howard, Cory M. "Characterization of the CXCR4-LASP1-eIF4F Axis in Triple-Negative Breast Cancer." University of Toledo Health Science Campus / OhioLINK, 2020. http://rave.ohiolink.edu/etdc/view?acc_num=mco1596298549051863.
Full textAbarca, Jacob. "The effect of beta-blocker therapy, ACE inhibitor therapy,and digoxin therapy on the risk of hospitalization and resource utilizationamong patients with congestive heart failure enrolled in a managed care organization." Thesis, The University of Arizona, 2001. http://hdl.handle.net/10150/291440.
Full textDuan, Qiming. "Cardiac Na/K-ATPase in Ischemia-Reperfusion Injury and Cardioprotection." University of Toledo Health Science Campus / OhioLINK, 2014. http://rave.ohiolink.edu/etdc/view?acc_num=mco1388151402.
Full textALEMANNI, MATTEO. "The modulation of SERCA pump activity as a tool for management of hearth failure." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2009. http://hdl.handle.net/10281/7462.
Full textClaassen, Marleen. "Exploring the contribution of prenatal stress to the pathogenesis of autism as a neurobiological developmental disorder : a dizygotic twin study." Diss., University of Pretoria, 2006. http://hdl.handle.net/2263/23190.
Full textDissertation (M.Ed)--University of Pretoria, 2006.
Educational Psychology
unrestricted
Weitkamp, Christine [Verfasser]. "Warum zeigen die Herzglykoside Ouabain und Digoxin unterschiedliche Kreislaufwirkung? : Charakterisierung eines mutmaßlichen Herzglykosid-Bindungsproteins im Serum und Analyse der Wirkung beider Steroide auf die Endothelin-1- und NO-Freisetzung aus arteriellen Endothelzellen / Christine Weitkamp." Wettenberg : VVB Laufersweiler, 2005. http://d-nb.info/976405792/34.
Full textHANOT, REGIS. "Tolerance de l'association digoxine - cibenzoline : impact des antiarythmiques sur le traitement par digoxine." Lille 2, 1993. http://www.theses.fr/1993LIL2M037.
Full textMoriau, Didier. "Aspects pharmacocinétiques de l'interaction digoxine-quinidine/." Paris 5, 1989. http://www.theses.fr/1989PA05P010.
Full textBoe͏̈l, Frédéric. "Automatisation du prélèvement et du dosage HPLC de l'essai de dissolution des comprimés de digoxine." Paris 5, 1994. http://www.theses.fr/1994PA05P189.
Full textMOLINARI, BENOIT PATRICIA. "La digoxine chez le sujet age : interet du dosage de la digoxinemie ; application pratique." Toulouse 3, 1992. http://www.theses.fr/1992TOU31089.
Full textCANO, CANO NATHALIE. "Evaluation de l'immunoreactivite d'anticorps anti-digoxine en immunotoxicotherapie." Paris 6, 1993. http://www.theses.fr/1993PA066706.
Full textPignotti, René-Pierre. "Digoxine et fonction ventriculaire gauche de la personne agee." Bordeaux 2, 1988. http://www.theses.fr/1988BOR25288.
Full textOweis, Shadi. "Cardiotonic Steroids Down-Regulate Sodium Hydrogen Exchanger Expression in the Proximal Tubule Cells." University of Toledo Health Science Campus / OhioLINK, 2010. http://rave.ohiolink.edu/etdc/view?acc_num=mco1278521957.
Full textCLADET, PHILIPPE. "Digoxine - digitaline : le choix du traitement face au risque de surdosage chez la personne agee : a propos de 46 observations." Lille 2, 1990. http://www.theses.fr/1990LIL2M029.
Full textDAMASE, LUC. "Recherches pharmacologiques sur le mecanisme d'interaction digoxine amiodarone chez l'homme." Toulouse 3, 1988. http://www.theses.fr/1988TOU31164.
Full textWahyono, Djoko. "Production et caractérisation d'anticorps monoclonaux dirigés contre la digoxine. Intérêt en immunoanalyse." Montpellier 1, 1990. http://www.theses.fr/1990MON13507.
Full textLAURANT, ERIC. "Intoxication grave au laurier rose : a propos d'un cas traite par les anticorps anti-digoxine." Clermont-Ferrand 1, 1991. http://www.theses.fr/1991CLF13061.
Full textGuedeney, Xavier. "Contribution à l'étude des composés digitaliques endogènes : propriétés immunologiques et biochimiques en période périnatale." Paris 5, 1988. http://www.theses.fr/1988PA05P614.
Full textBESSON, LAVEDAN SYLVIE. "Etude de la prescription de digoxine et de ses dosages seriques dans trente services du c. H. U. Purpan (toulouse) pendant deux ans." Toulouse 3, 1991. http://www.theses.fr/1991TOU31050.
Full textMarcaggi, P. "Intoxications digitaliques aigues : conduite a tenir en urgence ; interet de l'antidote anti-digoxine." Aix-Marseille 2, 1994. http://www.theses.fr/1994AIX20052.
Full textCommeau, Philippe. "Etude des variations de la pharmacocinétique et des effets pharmacodynamiques cardiovasculaires de la Digoxine sous l'influence de la coadministration de la Nicardipine chez l'homme en insuffisance cardiaque." Rouen, 1986. http://www.theses.fr/1986ROUE05NR.
Full textPOULAIN, GELARD YVETTE. "Traitement des intoxications digitaliques massives par les anticorps anti-digoxine fractionnes (fab) : a propos d'un cas, revue de la litterature." Nantes, 1989. http://www.theses.fr/1989NANT005M.
Full textNavarro-Teulon, Isabelle. "Ingénierie génétique des immunoglobulines appliquée au diagnostic et à l'immunoanalyse : mise au point d'un nouvel immunodosage de Digoxine, construction de banques combinatoires de fragments d'anticorps anti-thyroglobuline." Montpellier 1, 1995. http://www.theses.fr/1995MON13508.
Full textSalphati, Laurent. "P-glycoproteine et cytochrome p450 3a : interactions potentielles et roles complementaires dans l'absorption et la disposition des drogues." Paris 11, 1998. http://www.theses.fr/1998PA114805.
Full textMundet, i. Tudurí Xavier. "Estudi de la utilització de la digoxina. Utilitat de la digoxinèmia com a marcador del seu ús." Doctoral thesis, Universitat Autònoma de Barcelona, 1990. http://hdl.handle.net/10803/5401.
Full textLacarelle, Bruno. "Contribution de la pharmacocinetique a la maitrise et a l'elucidation des origines de la variabilite de la reponse therapeutique : applications aux aminosides et a la digoxine." Aix-Marseille 2, 1988. http://www.theses.fr/1988AIX22963.
Full textReibel, Monique. "Le dosage des digitaliques chez l'hemodialyse : pharmacocinetique de la digitoxine, presence d'une activite digitalis-like endogene." Strasbourg 1, 1988. http://www.theses.fr/1988STR1M058.
Full text